Evidence map›Paper›PMID 27538497›Full record

Trial reportBMC complementary and alternative medicine2016

The effect of Vaccinium uliginosum extract on tablet computer-induced asthenopia: randomized placebo-controlled study.

Choul Yong Park, Namyi Gu, Chi-Yeon Lim, Jong-Hyun Oh, Minwook Chang, Martha Kim, Moo-Yong Rhee

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC complementary and alternative medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02641470 (Clinical Trial to Investigate the Effect of DA9301 on Tablet Computer-induced Asthenopia in Humans), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02641470 nacompletednot on this map

Clinical Trial to Investigate the Effect of DA9301 on Tablet Computer-induced Asthenopia in Humans

TypeinterventionalSponsorNamyi GuRan2014Enrolled60ConditionsAsthenopiaArmsDA9301 (Vaccinium uliginosum extract), Placebo
3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Is critical flicker-fusion frequency a valid measure of visual fatigue? A post-hoc analysis of a double-masked randomised controlled trial.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2023
    Trial
  2. Trial
  3. Review
  4. Nutrients · 2023
    Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Choul Yong ParkDepartment of Ophthalmology, Dongguk University, Ilsan Hospital, Goyang, Gyeonggido, South Korea. oph0112@gmail.com.
Namyi GuDepartment of Clinical Pharmacology and Therapeutics, Dongguk University, Ilsan Hospital, Goyang, Gyeonggido, South Korea.
Chi-Yeon LimDepartment of Biostatistics, Dongguk University Ilsan Hospital, Goyang, Gyeonggido, South Korea.
Jong-Hyun OhDepartment of Ophthalmology, Dongguk University, Ilsan Hospital, Goyang, Gyeonggido, South Korea.
Minwook ChangDepartment of Ophthalmology, Dongguk University, Ilsan Hospital, Goyang, Gyeonggido, South Korea.
Martha KimDepartment of Ophthalmology, Dongguk University, Ilsan Hospital, Goyang, Gyeonggido, South Korea.
Moo-Yong RheeDepartment of Cardiology, Dongguk University, Ilsan Hospital, Goyang, Gyeonggido, South Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo investigate the alleviation effect of Vaccinium uliginosum extract (DA9301) on tablet computer-induced asthenopia.

methodsThis was a randomized, placebo-controlled, double-blind and parallel study (Trial registration number: 2013-95). A total 60 volunteers were randomized into DA9301 (n = 30) and control (n = 30) groups. The DA9301 group received DA9301 oral pill (1000 mg/day) for 4 weeks and the control group received placebo. Asthenopia was evaluated by administering a questionnaire containing 10 questions (responses were scored on a scales of 0-6; total score: 60) regarding ocular symptoms before (baseline) and 4 weeks after receiving pills (DA9301 or placebo). The participants completed the questionnaire before and after tablet computer (iPad Air, Apple Inc.) watching at each visit. The change in total asthenopia score (TAS) was calculated and compared between the groups

resultsTAS increased significantly after tablet computer watching at baseline in DA9301 group. (from 20.35 to 23.88; p = 0.031) However, after receiving DA9301 for 4 weeks, TAS remained stable after tablet computer watching. In the control group, TAS changes induced by tablet computer watching were not significant both at baseline and at 4 weeks after receiving placebo. Further analysis revealed the scores for "tired eyes" (p = 0.001), "sore/aching eyes" (p = 0.038), "irritated eyes" (p = 0.010), "watery eyes" (p = 0.005), "dry eyes" (p = 0.003), "eye strain" (p = 0.006), "blurred vision" (p = 0.034), and "visual discomfort" (p = 0.018) significantly improved in the DA9301 group.

conclusionsWe found that oral intake of DA9301 (1000 mg/day for 4 weeks) was effective in alleviating asthenopia symptoms induced by tablet computer watching.

trial registrationThe study is registered at www.clinicaltrials.gov (registration number: NCT02641470, date of registration December 30, 2015).

Indexed as

Administration, OralAdultAntioxidantsAsthenopiaBlueberry PlantsComputersFemaleHumansMaleMiddle AgedPlant ExtractsSurveys and QuestionnairesYoung AdultAntioxidantsPlant ExtractsAntioxidantAsthenopiaBillberryComputer vision syndromeVaccinium

Identifiers

PMID27538497
PMCPMC4991001

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.